To include your compound in the COVID-19 Resource Center, submit it here.

Regulus sinks on clinical hold

Regulus Therapeutics Inc. (NASDAQ:RGLS) said FDA placed a full clinical hold on RG-101 after the company reported a second case of jaundice, a severe

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE